Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Donald E. Cutlip, M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U01HL081656 (CUTLIP, DONALD) Aug 15, 2005 - Jul 31, 2013
    NIH
    Claudication Exercise vs Endoluminal Revascularization
    Role: Principal Investigator
  2. U01HL072737 (CUTLIP, DONALD) Apr 15, 2004 - Jul 31, 2015
    NIH
    CORAL: Data Coordinating Center
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Modrall JG, Zhu H, Prasad T, Moe O, Dworkin LD, Cutlip DE, Murphy TP, Cooper CJ, Toto R. Retrieval of Renal Function After Renal Artery Stenting Improves Event-Free Survival in a Sub-group Analysis of the Cardiovascular Outcomes in Renal Atherosclerotic Lesions Trial. J Vasc Surg. 2023 Feb 01. PMID: 36736864.
    Citations:    Fields:    
  2. Korjian S, Yeh RW, Cutlip DE. Ischemic Risk Prediction Scores: Practice-Changing or Just Practice? J Am Coll Cardiol. 2022 11 01; 80(18):1748-1750. PMID: 36302587.
    Citations:    Fields:    Translation:Humans
  3. Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents: BIOFLOW V Final 5-Year Outcomes. JACC Cardiovasc Interv. 2022 09 26; 15(18):1852-1860. PMID: 36137689.
    Citations:    Fields:    Translation:Humans
  4. Lunardi M, Louvard Y, Lefèvre T, Stankovic G, Burzotta F, Kassab GS, Lassen JF, Darremont O, Garg S, Koo BK, Holm NR, Johnson TW, Pan M, Chatzizisis YS, Banning A, Chieffo A, Dudek D, Hildick-Smith D, Garot J, Henry TD, Dangas G, Stone GW, Krucoff MW, Cutlip D, Mehran R, Wijns W, Sharif F, Serruys PW, Onuma Y. Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. J Am Coll Cardiol. 2022 07 05; 80(1):63-88. PMID: 35597684.
    Citations: 2     Fields:    Translation:Humans
  5. Lunardi M, Louvard Y, Lefèvre T, Stankovic G, Burzotta F, Kassab GS, Lassen JF, Darremont O, Garg S, Koo BK, Holm NR, Johnson TW, Pan M, Chatzizisis YS, Banning AP, Chieffo A, Dudek D, Hildick-Smith D, Garot J, Henry TD, Dangas G, Stone G, Krucoff MW, Cutlip D, Mehran R, Wijns W, Sharif F, Serruys PW, Onuma Y. Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention. 2022 May 18. PMID: 35583108.
    Citations: 2     Fields:    
  6. Cutlip DE, Mehran R, Spitzer E, Morice MC, Krucoff MW. Device and Procedure Relatedness: Viewpoint From Members of the ARC Steering Group. JACC Cardiovasc Interv. 2022 04 11; 15(7):783-788. PMID: 35393110.
    Citations:    Fields:    
  7. Borlaug BA, Blair J, Bergmann MW, Bugger H, Burkhoff D, Bruch L, Celermajer DS, Claggett B, Cleland JGF, Cutlip DE, Dauber I, Eicher JC, Gao Q, Gorter TM, Gustafsson F, Hayward C, van der Heyden J, Hasenfuß G, Hummel SL, Kaye DM, Komtebedde J, Massaro JM, Mazurek JA, McKenzie S, Mehta SR, Petrie MC, Post MC, Nair A, Rieth A, Silvestry FE, Solomon SD, Trochu JN, Van Veldhuisen DJ, Westenfeld R, Leon MB, Shah SJ. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation. 2022 05 24; 145(21):1592-1604. PMID: 35354306; PMCID: PMC9133195.
    Citations: 4     Fields:    Translation:Humans
  8. Kandzari DE, Mahfoud F, Weber MA, Townsend R, Parati G, Fisher NDL, Lobo MD, Bloch M, Böhm M, Sharp ASP, Schmieder RE, Azizi M, Schlaich MP, Papademetriou V, Kirtane AJ, Daemen J, Pathak A, Ukena C, Lurz P, Grassi G, Myers M, Finn AV, Morice MC, Mehran R, Jüni P, Stone GW, Krucoff MW, Whelton PK, Tsioufis K, Cutlip DE, Spitzer E. Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation. 2022 03 15; 145(11):847-863. PMID: 35286164; PMCID: PMC8912966.
    Citations: 4     Fields:    Translation:Humans
  9. Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, Gao Q, Hasenfuß G, Kahwash R, Kaye DM, Litwin SE, Lurz P, Massaro JM, Mohan RC, Ricciardi MJ, Solomon SD, Sverdlov AL, Swarup V, van Veldhuisen DJ, Winkler S, Leon MB. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet. 2022 03 19; 399(10330):1130-1140. PMID: 35120593.
    Citations: 14     Fields:    Translation:Humans
  10. Mihatov N, Secemsky EA, Kereiakes DJ, Steg PG, Cutlip DE, Kirtane AJ, Mehran R, Zhao B, Song Y, Gibson CM, Yeh RW. Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study. Cardiovasc Revasc Med. 2022 08; 41:105-112. PMID: 35045941.
    Citations:    Fields:    Translation:Humans
  11. Cutlip DE, Jauhar R, Meraj P, Garratt KN, Novack V, Novack L, Maillard L, Erglis A, Stoler R, Barakat M, Silber S. Five-Year Clinical Outcomes of the COBRA Polyzene F NanoCoated Coronary Stent System. Cardiovasc Revasc Med. 2022 08; 41:76-80. PMID: 35045942.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  12. Cutlip DE. ROSES - Avoiding the Thorns. Cardiovasc Revasc Med. 2022 03; 36:71-72. PMID: 34952821.
    Citations:    Fields:    Translation:HumansAnimals
  13. Gibson CM, Mack MJ, Lee VT, Schneider DJ, Sellke FW, Ohman EM, Thourani VH, Doros G, Kroger H, Cutlip DE, Deliargyris EN. Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. Am Heart J. 2022 03; 245:19-28. PMID: 34736855.
    Citations: 1     Fields:    Translation:Humans
  14. Kereiakes DJ, Feldman RL, Ijsselmuiden AJJ, Saito S, Amoroso G, Zidar JP, Wong SC, Stella P, Yakubov S, Lasala J, Cohen DJ, Doros G, Cutlip DE, Rao SV. Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study. Circ Cardiovasc Interv. 2021 09; 14(9):e010609. PMID: 34353122.
    Citations:    Fields:    Translation:Humans
  15. Berg DD, Yeh RW, Mauri L, Morrow DA, Kereiakes DJ, Cutlip DE, Gao Q, Jarolim P, Michelson AD, Frelinger AL, Cange AL, Sabatine MS, O'Donoghue ML. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. PMID: 32683645.
    Citations: 4     Fields:    Translation:Humans
  16. Cutlip DE. Standing the Test of Time: A Device and Patient Perspective. J Am Coll Cardiol. 2021 03 09; 77(9):1179-1181. PMID: 33663734.
    Citations:    Fields:    Translation:Humans
  17. Ybarra LF, Rinfret S, Brilakis ES, Karmpaliotis D, Azzalini L, Grantham JA, Kandzari DE, Mashayekhi K, Spratt JC, Wijeysundera HC, Ali ZA, Buller CE, Carlino M, Cohen DJ, Cutlip DE, De Martini T, Di Mario C, Farb A, Finn AV, Galassi AR, Gibson CM, Hanratty C, Hill JM, Jaffer FA, Krucoff MW, Lombardi WL, Maehara A, Magee PFA, Mehran R, Moses JW, Nicholson WJ, Onuma Y, Sianos G, Sumitsuji S, Tsuchikane E, Virmani R, Walsh SJ, Werner GS, Yamane M, Stone GW, Rinfret S, Stone GW. Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. Circulation. 2021 02 02; 143(5):479-500. PMID: 33523728.
    Citations: 22     Fields:    Translation:Humans
  18. Colleran R, Joner M, Cutlip D, Urban P, Maeng M, Jauhar R, Barakat M, Michel JM, Mehran R, Kirtane AJ, Maillard L, Kastrati A, Byrne RA. Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). Cardiovasc Revasc Med. 2022 01; 34:17-24. PMID: 33608239.
    Citations: 3     Fields:    Translation:Humans
  19. Katritsis DG, Pantos I, Zografos T, Spahillari A, de Waha A, Kopanidis A, Foussas S, Stone PH, Kastrati A, Cutlip D. Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. Am J Cardiol. 2021 02 15; 141:7-15. PMID: 33220322.
    Citations: 1     Fields:    Translation:Humans
  20. Cutlip DE. Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. J Am Coll Cardiol. 2020 10 06; 76(14):1640-1643. PMID: 33004128.
    Citations: 7     Fields:    Translation:Humans
  21. Capodanno D, Morice MC, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 09 22; 76(12):1468-1483. PMID: 32943165.
    Citations: 6     Fields:    Translation:Humans
  22. Marquis-Gravel G, Moliterno DJ, Francis DP, Jüni P, Rosenberg YD, Claessen BE, Mentz RJ, Mehran R, Cutlip DE, Chauhan C, Quella S, Zannad F, Goodman SG. Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 07 28; 76(4):435-450. PMID: 32703515; PMCID: PMC10018282.
    Citations: 1     Fields:    Translation:Humans
  23. Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial. JACC Cardiovasc Interv. 2020 06 08; 13(11):1343-1353. PMID: 32499026.
    Citations: 13     Fields:    Translation:Humans
  24. Cutlip DE. On the Bleeding Edge: Device- or Drug-Based Solutions. Circ Cardiovasc Interv. 2020 04; 13(4):e009128. PMID: 32279569.
    Citations:    Fields:    Translation:Humans
  25. Cutlip DE. Editorial: A REMEDEE for Very Late Stent Failure? Cardiovasc Revasc Med. 2020 05; 21(5):571-572. PMID: 32061486.
    Citations:    Fields:    Translation:Humans
  26. Spitzer E, McFadden E, Rademaker-Havinga T, Cutlip DE, Garcia-Garcia HM. Reply: Periprocedural PCI Myocardial Biomarker Elevation and Mortality. JACC Cardiovasc Interv. 2020 01 27; 13(2):266-268. PMID: 31973800.
    Citations:    Fields:    Translation:Humans
  27. Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, Lansky AJ, Mehran R, Spitzer E, Fraser AG, Baumbach A, Serruys PW. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention. 2020 Jan 17; 15(13):1190-1198. PMID: 31475907.
    Citations: 1     Fields:    Translation:Humans
  28. Cutlip DE, Urban P. Validation of Standardization: Testing the Academic Research Consortium High Bleeding Risk Criteria. Circ Cardiovasc Interv. 2019 11; 12(11):e008569. PMID: 31707806.
    Citations:    Fields:    Translation:Humans
  29. Cutlip DE. Diabetes, Kidney Disease, and Coronary Stents - A Complex Interaction. Cardiovasc Revasc Med. 2019 12; 20(12):1081-1082. PMID: 31870525.
    Citations:    Fields:    Translation:Humans
  30. Garcia-Garcia HM, McFadden EP, von Birgelen C, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P. Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 10 14; 12(19):1954-1962. PMID: 31601389.
    Citations: 16     Fields:    Translation:HumansCells
  31. Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay JF, Hsieh WH, Massaro JM, Mauri L, Cutlip DE. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820. PMID: 31653353.
    Citations: 4     Fields:    Translation:Humans
  32. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 08 14; 40(31):2632-2653. PMID: 31116395; PMCID: PMC6736433.
    Citations: 86     Fields:    Translation:Humans
  33. Cooper EL, Xie Y, Nguyen H, Brewster PS, Sholl H, Sharrett M, Ren K, Chen T, Tuttle KR, Haller ST, Jamerson K, Murphy TP, D'Agostino RB, Massaro JM, Henrich W, Cooper CJ, Cutlip DE, Dworkin LD, Shapiro JI. Early Rapid Decline in Kidney Function in Medically Managed Patients With Atherosclerotic Renal Artery Stenosis. J Am Heart Assoc. 2019 06 04; 8(11):e012366. PMID: 31433717.
    Citations: 5     Fields:    Translation:Humans
  34. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 07 16; 140(3):240-261. PMID: 31116032; PMCID: PMC6636810.
    Citations: 98     Fields:    Translation:Humans
  35. Spitzer E, McFadden E, Vranckx P, Garcia-Garcia HM, Seltzer JH, Held C, de Vries T, Menon V, Brown KJ, Soliman OII, Onuma Y, Lopes RD, Stone GW, Cutlip DE, Serruys PW. Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. JACC Cardiovasc Interv. 2019 05 13; 12(9):805-819. PMID: 31072504.
    Citations: 4     Fields:    Translation:Humans
  36. Chen T, Brewster P, Tuttle KR, Dworkin LD, Henrich W, Greco BA, Steffes M, Tobe S, Jamerson K, Pencina K, Massaro JM, D'Agostino RB, Cutlip DE, Murphy TP, Cooper CJ, Shapiro JI. Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study. Int J Nephrol Renovasc Dis. 2019; 12:49-58. PMID: 30962703; PMCID: PMC6433104.
    Citations: 2     
  37. Jones MR, Howard G, Roubin GS, Blackshear JL, Cohen DJ, Cutlip DE, Leimgruber PP, Rhodes D, Prineas RJ, Glasser SP, Lal BK, Voeks JH, Brott TG. Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. Circ Cardiovasc Qual Outcomes. 2018 11; 11(11):e004663. PMID: 30571337; PMCID: PMC6309309.
    Citations: 7     Fields:    Translation:Humans
  38. Roguin A, Kandzari DE, Marcusohn E, Koolen JJ, Doros G, Massaro JM, Garcia-Garcia HM, Bennett J, Gharib EG, Cutlip DE, Waksman R. Subgroup Analysis Comparing Ultrathin, Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin, Durable Polymer Everolimus-Eluting Stents in Acute Coronary Syndrome Patients. Circ Cardiovasc Interv. 2018 10; 11(10):e007331. PMID: 30354631.
    Citations: 8     Fields:    Translation:Humans
  39. Kandzari DE, Koolen JJ, Doros G, Massaro JJ, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. J Am Coll Cardiol. 2018 12 25; 72(25):3287-3297. PMID: 30257191.
    Citations: 16     Fields:    Translation:Humans
  40. Berry NC, Kereiakes DJ, Yeh RW, Steg PG, Cutlip DE, Jacobs AK, Abbott JD, Hsieh WH, Massaro JM, Mauri L. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308. PMID: 30354781.
    Citations: 2     Fields:    Translation:Humans
  41. Cutlip DE, Fischman DL. Mortality After Percutaneous Coronary Intervention: Narrowing the Knowledge Gap. Circ Cardiovasc Interv. 2018 07; 11(7):e007008. PMID: 30006335.
    Citations: 2     Fields:    Translation:Humans
  42. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018 06 14; 39(23):2192-2207. PMID: 29897428.
    Citations: 40     Fields:    Translation:Humans
  43. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 06 12; 137(24):2635-2650. PMID: 29891620.
    Citations: 100     Fields:    Translation:Humans
  44. Spitzer E, McFadden E, Vranckx P, de Vries T, Ren B, Collet C, Onuma Y, Garcia-Garcia HM, Lopes RD, Stone GW, Cutlip DE, Serruys PW. Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document. JACC Cardiovasc Interv. 2018 05 14; 11(9):823-832. PMID: 29747912.
    Citations: 3     Fields:    Translation:Humans
  45. Lansky AJ, Messé SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J. 2018 05 14; 39(19):1687-1697. PMID: 28171522; PMCID: PMC6251670.
    Citations: 4     Fields:    Translation:Humans
  46. Ruiz CE, Hahn RT, Berrebi A, Borer JS, Cutlip DE, Fontana G, Gerosa G, Ibrahim R, Jelnin V, Jilaihawi H, Jolicoeur EM, Kliger C, Kronzon I, Leipsic J, Maisano F, Millan X, Nataf P, O'Gara PT, Pibarot P, Ramee SR, Rihal CS, Rodes-Cabau J, Sorajja P, Suri R, Swain JA, Turi ZG, Tuzcu EM, Weissman NJ, Zamorano JL, Serruys PW, Leon MB. Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. Eur Heart J. 2018 04 14; 39(15):1224-1245. PMID: 28430909.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  47. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 03 06; 71(9):1021-1034. PMID: 29495982.
    Citations: 76     Fields:    Translation:Humans
  48. Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ. 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018 02 27; 137(9):961-972. PMID: 29483172.
    Citations: 115     Fields:    Translation:Humans
  49. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van de Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O'Gara PT, Fox KAA. [Fourth universal definition of myocardial infarction (2018)]. Kardiol Pol. 2018; 76(10):1383-1415. PMID: 30338834.
    Citations: 17     Fields:    Translation:Humans
  50. Stefanini GG, Cutlip D. Sorting out coronary stents, as time goes by. EuroIntervention. 2017 12 20; 13(11):1263-1265. PMID: 29260717.
    Citations:    Fields:    
  51. Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223. PMID: 29073947; PMCID: PMC7754792.
    Citations: 23     Fields:    Translation:Humans
  52. Kandzari DE, Mauri L, Koolen JJ, Massaro JM, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, Gharib EG, Cutlip DE, Waksman R. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 390(10105):1843-1852. PMID: 28851504.
    Citations: 53     Fields:    Translation:Humans
  53. Doros G, Massaro JM, Kandzari DE, Waksman R, Koolen JJ, Cutlip DE, Mauri L. Rationale of a novel study design for the BIOFLOW V study, a prospective, randomized multicenter study to assess the safety and efficacy of the Orsiro sirolimus-eluting coronary stent system using a Bayesian approach. Am Heart J. 2017 Nov; 193:35-45. PMID: 29129253.
    Citations: 2     Fields:    Translation:Humans
  54. Lam DH, Glassmoyer LM, Strom JB, Davis RB, McCabe JM, Cutlip DE,